WO2020132366A3 - Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés - Google Patents

Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés Download PDF

Info

Publication number
WO2020132366A3
WO2020132366A3 PCT/US2019/067676 US2019067676W WO2020132366A3 WO 2020132366 A3 WO2020132366 A3 WO 2020132366A3 US 2019067676 W US2019067676 W US 2019067676W WO 2020132366 A3 WO2020132366 A3 WO 2020132366A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
epitope
cancer
mod
modulatory multimeric
Prior art date
Application number
PCT/US2019/067676
Other languages
English (en)
Other versions
WO2020132366A2 (fr
WO2020132366A4 (fr
Inventor
Ronald D. Seidel, Iii
Rodolfo J. Chaparro
John F. Ross
Chee Meng Low
Original Assignee
Cue Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma, Inc. filed Critical Cue Biopharma, Inc.
Publication of WO2020132366A2 publication Critical patent/WO2020132366A2/fr
Publication of WO2020132366A3 publication Critical patent/WO2020132366A3/fr
Publication of WO2020132366A4 publication Critical patent/WO2020132366A4/fr
Priority to US17/342,513 priority Critical patent/US20220008467A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des polypeptides multimères modulateurs des lymphocytes T ("T-Cell-MMP") comprenant un polypeptide immunomodulateur ("MOD") qui peuvent être sélectionnés pour présenter une affinité de liaison réduite à un polypeptide co-immunomodulateur parent ("Co-MOD") et un peptide de présentation d'épitope du tumeur de Wilms (WT-1) conjugué. Les conjugués lymphocyte T-MMP-épitope sont utiles pour moduler l'activité d'un lymphocyte T par administration de peptides immunomodulateurs, tels que des IL-2 ou des variants d'IL-2 qui présentent une affinité de liaison réduite à IL-2R, pour les lymphocytes T d'une manière sélective/spécifique d'un épitope WT-1, et par conséquent, pour le traitement d'individus, en particulier ceux atteints d'une leucémie myéloïde aigue, d'un myélome, d'un cancer de l'ovaire, d'un cancer du pancréas, d'un cancer du poumon non à petites cellules, d'un cancer colorectal, d'un cancer du sein, d'une tumeur de Wilms, d'un mésothéliome, d'un sarcome des tissus mous, d'un neuroblastome ou d'un néphroblastome.
PCT/US2019/067676 2018-12-19 2019-12-19 Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés WO2020132366A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/342,513 US20220008467A1 (en) 2018-12-19 2021-06-08 T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782245P 2018-12-19 2018-12-19
US62/782,245 2018-12-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/342,513 Continuation US20220008467A1 (en) 2018-12-19 2021-06-08 T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof

Publications (3)

Publication Number Publication Date
WO2020132366A2 WO2020132366A2 (fr) 2020-06-25
WO2020132366A3 true WO2020132366A3 (fr) 2020-07-23
WO2020132366A4 WO2020132366A4 (fr) 2020-09-24

Family

ID=71101640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/067676 WO2020132366A2 (fr) 2018-12-19 2019-12-19 Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés

Country Status (2)

Country Link
US (1) US20220008467A1 (fr)
WO (1) WO2020132366A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
JP7549579B2 (ja) * 2018-12-19 2024-09-11 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節ポリペプチド及びその使用方法
CN116437952A (zh) * 2020-07-14 2023-07-14 库尔生物制药有限公司 具有缀合位点的t细胞调节多肽及其使用方法
EP4211149A4 (fr) 2020-09-09 2024-10-09 Cue Biopharma Inc Polypeptides multimères modulateurs des lymphocytes t du cmh de classe ii pour le traitement du diabète sucré de type 1 (dt1) et leurs procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170334951A1 (en) * 2012-01-13 2017-11-23 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
WO2018129474A1 (fr) * 2017-01-09 2018-07-12 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016303497A1 (en) * 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
KR101769025B1 (ko) * 2015-08-04 2017-08-17 전남대학교산학협력단 브랜치드 멀티펩티드 조성물 및 이를 포함하는 백신
CA3022227A1 (fr) * 2016-04-27 2017-11-02 University Health Network (Uhn) Complexes de hla peptidique et procedes pour leur production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170334951A1 (en) * 2012-01-13 2017-11-23 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
WO2018129474A1 (fr) * 2017-01-09 2018-07-12 Cue Biopharma, Inc. Polypeptides multimères modulateurs de lymphocytes t et leurs procédés d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEBEISEN ET AL.: "Identification of Rare High-Avidity, Tumor-Reactive CD 8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells", CANCER RESEARCH, vol. 75, no. 10, 2015, pages OF1 - OF10, XP055310347, DOI: 10.1158/0008-5472.CAN-14-3516 *

Also Published As

Publication number Publication date
WO2020132366A2 (fr) 2020-06-25
WO2020132366A4 (fr) 2020-09-24
US20220008467A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
WO2020132366A3 (fr) Polypeptides multimères modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés
EP4389145A3 (fr) Conjugués polypeptidiques d'interleukine-2 et leurs utilisations
MX2021011997A (es) Enlazadores de conjugacion mejorados.
NZ756763A (en) Engineered transferrin receptor binding polypeptides
PH12019501056A1 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
MX2022011818A (es) Metodos y composiciones para el direccionamiento de canceres de celulas t.
WO2016130819A3 (fr) Compositions et méthodes de polythérapie combinées à des protéines se liant à l'antigène membranaire spécifique de la prostate
AU2018271872A1 (en) A protein binding NKG2D, CD16 and ROR1 or ROR2
WO2022099156A3 (fr) Polypeptides modulateurs de lymphocytes t comportant des sites de conjugaison et méthodes d'utilisation associées
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
EP4257186A3 (fr) Conjugués de médicament et d'élément d'affinité
WO2022015880A3 (fr) Polypeptides modulateurs des lymphocytes t ayant des sites de conjugaison et procédés d'utilisation associés
EP4035675A3 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MX2022003195A (es) Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga.
MX2021007287A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
ZA202107947B (en) Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
WO2022082073A3 (fr) Compositions et méthodes de ciblage de muc18
CL2020002948A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer (divisional de la solicitud 201902878)
PH12021550581A1 (en) Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods
MX2022004598A (es) Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
WO2023137156A3 (fr) Polypeptides modulateurs de lymphocyte t avec sites de conjugaison et leurs méthodes d'utilisation
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
WO2018175740A8 (fr) Anticorps anti-tmeff1 et conjugués anticorps-médicament
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.
MX2024002407A (es) Anticuerpos y conjugados sirp-alfa.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19899709

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19899709

Country of ref document: EP

Kind code of ref document: A2